Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease.

Fatos Belgin Yildirim, Ozlem Ozsoy, Gamze Tanriover, Yasemin Kaya, Eren Ogut, Burcu Gemici, Sayra Dilmac, Ayse Ozkan, Aysel Agar, Mutay Aslan

Overview

This study aimed to elucidate locomotor activity changes in 6-hydroxydopamine (6-OHDA) induced Parkinson's disease (PD) and investigate the possible beneficial effects of melatonin on altered levels of locomotor activity, cyclooxygenase (COX), prostaglandin E2 (PGE2), nuclear factor kappa-B (NF-?B), nitrate/nitrite and apoptosis. Male Wistar rats were divided into five groups: vehicle (V), melatonin-treated (M), 6-OHDA-injected (6-OHDA), 6-OHDA-injected + melatonin-treated (6-OHDA-Mel) and melatonin treated + 6-OHDA-injected (Mel-6-OHDA). Melatonin was administered intraperitoneally at a dose of 10 mg/kg/day for 30 days in M and Mel-6-OHDA groups, for 7 days in 6-OHDA-Mel group. Experimental PD was created stereotactically via unilateral infusion of 6-OHDA into the medial forebrain bundle (MFB).

Summary

Melatonin supplementation decreased dopaminergic neuron death in 6-OHDA-Mel and Mel-6-OHDA groups compared with 6-OHDA group. Melatonin also protected against 6-OHDA-induced apoptosis, as identified by increment in Bcl-2 levels in dopaminergic neurons. The protective effect of melatonin was more prominent for most parameter following 30 days treatment (pre- and post-) than 7 days post-treatment.

Altmetric Statistics

Author Comments

Dr.  erenogut, PhD
Dr. erenogut, PhD
Department of Anatomy / Bahcesehir University School of Medicine
Asst. Prof.
Anatomy
Istanbul | Turkey
melatonin treatment decreased dopaminergic neuron death in experimental PD model by increasing Bcl-2 protein level and decreasing caspase-3 activity.Dr. erenogut, PhD

Resources

Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease.

Authors:
Dr.  erenogut, PhD
Dr. erenogut, PhD
Department of Anatomy / Bahcesehir University School of Medicine
Asst. Prof.
Anatomy
Istanbul | Turkey

Neurochem Int 2014 Dec 28;79:1-11. Epub 2014 Sep 28.

Faculty of Medicine, Department of Biochemistry, Akdeniz University, Antalya, Turkey.

This study aimed to elucidate locomotor activity changes in 6-hydroxydopamine (6-OHDA) induced Parkinson's disease (PD) and investigate the possible beneficial effects of melatonin on altered levels of locomotor activity, cyclooxygenase (COX), prostaglandin E2 (PGE2), nuclear factor kappa-B (NF-?B), nitrate/nitrite and apoptosis. Male Wistar rats were divided into five groups: vehicle (V), melatonin-treated (M), 6-OHDA-injected (6-OHDA), 6-OHDA-injected + melatonin-treated (6-OHDA-Mel) and melatonin treated + 6-OHDA-injected (Mel-6-OHDA). Melatonin was administered intraperitoneally at a dose of 10 mg/kg/day for 30 days in M and Mel-6-OHDA groups, for 7 days in 6-OHDA-Mel group. Experimental PD was created stereotactically via unilateral infusion of 6-OHDA into the medial forebrain bundle (MFB). The 6-OHDA-Mel group started receiving melatonin when experimental PD was created and treatment was continued for 7 days (post-treatment). In the Mel-6-OHDA group, experimental PD was created on the 23rd day of melatonin treatment and continued for the remaining 7 days (pre- and post-treatment). Locomotor activity performance decreased in 6-OHDA group compared with vehicle; however melatonin treatment did not improve this impairment. Nuclear factor kappa Bp65 and Bcl-2 levels were significantly decreased while COX, PGE2 and caspase-3 activity were significantly increased in 6-OHDA group. Melatonin treatment significantly decreased COX, PGE2 and caspase-3 activity, increased Bcl-2 and had no effect on NF-?B levels in experimental PD. 6-Hydroxydopamine injection caused an obvious reduction in TH positive dopaminergic neuron viability as determined by immunohistochemistry. Melatonin supplementation decreased dopaminergic neuron death in 6-OHDA-Mel and Mel-6-OHDA groups compared with 6-OHDA group. Melatonin also protected against 6-OHDA-induced apoptosis, as identified by increment in Bcl-2 levels in dopaminergic neurons. The protective effect of melatonin was more prominent for most parameter following 30 days treatment (pre- and post-) than 7 days post-treatment. In summary, melatonin treatment decreased dopaminergic neuron death in experimental PD model by increasing Bcl-2 protein level and decreasing caspase-3 activity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuint.2014.09.005DOI Listing
December 2014
16 Reads
24 Citations
3.092 Impact Factor

Publication Analysis

Top Keywords

melatonin treatment
16
experimental created
12
locomotor activity
12
6-ohda group
12
caspase-3 activity
12
melatonin
12
dopaminergic neuron
12
neuron death
8
decreased dopaminergic
8
bcl-2 levels
8
days post-treatment
8
treatment continued
8
nuclear factor
8
activity increased
8
mel-6-ohda groups
8
decreased cox
8
parkinson's disease
8
cox pge2
8
group melatonin
8
treatment decreased
8

Similar Publications